MedTrace Logo

Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease

NCT05737602 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-05-29

No results posted yet for this study

Summary

The Relaxation Response Resiliency Program (3RP) has shown efficacy in improving coping and resilience across diverse populations; however, little is known about how it helps individuals manage the challenges of living with a chronic illness. This study proposes to pilot test an adapted version of the 3RP among patients living with VHL.

Conditions

  • Von Hippel-Lindau Disease
  • Genetic Disorder

Interventions

BEHAVIORAL

3RP-VHL

An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals with VHL.

Sponsors & Collaborators

  • The Rappaport Foundation

    collaborator UNKNOWN

  • The Claflin Distinguished Scholar Awards

    collaborator UNKNOWN

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Giselle Perez, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-30
Primary Completion
2026-05-01
Completion
2026-07-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05737602 on ClinicalTrials.gov